Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 11/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30115000 | 0.90 | AGTR2 (0.38) | AGTR2AGTR1 | |
| SCHEMBL21470296 | 0.90 | AGTR2 (0.38) | AGTR2AGTR1 | |
| SCHEMBL2351543 | 0.89 | AGTR2 (0.43) | AGTR2AGTR1 | |
| SCHEMBL30114895 | 0.89 | AGTR2 (0.43) | AGTR2AGTR1 | |
| SCHEMBL6713139 | 0.87 | PTGER4 (0.40) | AGTR2AGTR1 | |
| SCHEMBL2356746 | 0.86 | PTGER4 (0.48) | AGTR2AGTR1 | |
| SCHEMBL1626050 | 0.86 | AGTR2 (0.39) | AGTR2AGTR1 | |
| SCHEMBL21470061 | 0.83 | MCL1 (0.38) | AGTR2AGTR1 | |
| SCHEMBL30114814 | 0.83 | MCL1 (0.38) | AGTR2AGTR1 | |
| SCHEMBL2351917 | 0.82 | HRH3 (0.38) | AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | AGTR2 911/4885AGTR1 827/4885CTSB 2036/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | AGTR2 274/4885AGTR1 264/4885CTSB 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.